EGFR and cancer: Afatinib also shows activity against cancers resistant to first-generation EGFR inhibitors due to certain activating EGFR mutations, secondary EGFR mutations such as T790M or tumours expressing other ErbB family receptors activated by drug-induced reprogramming of signalling pathways.